Bristol-Myers Squibb Company (BMY)
| Market Cap | 127.01B |
| Revenue (ttm) | 48.19B |
| Net Income (ttm) | 7.05B |
| Shares Out | 2.04B |
| EPS (ttm) | 3.46 |
| PE Ratio | 18.03 |
| Forward PE | 9.95 |
| Dividend | $2.52 (4.12%) |
| Ex-Dividend Date | Jan 2, 2026 |
| Volume | 20,742,017 |
| Open | 61.18 |
| Previous Close | 61.10 |
| Day's Range | 61.18 - 62.68 |
| 52-Week Range | 42.52 - 63.33 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 61.93 (-0.71%) |
| Earnings Date | Feb 5, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for BMY stock is "Buy." The 12-month stock price target is $61.93, which is a decrease of -0.71% from the latest price.
News
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treat...
NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the N...
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference.
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia.
Bristol-Myers: I'm Buying Post Earnings
Bristol-Myers: I'm Buying Post Earnings
Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
Bristol-Myers Squibb Company ended 2025 and started this year on a high note. On February 6, its stock reached a 52-week high of $63.3. One of the reasons BMY is once again becoming a Wall Street favo...
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or Refractory Multiple Myeloma.
Best Stocks Outside The Mag 7 To Balance Growth And High Yield
Markets in 2026 are rewarding selectivity rather than size alone. Mega-cap leadership has narrowed, volatility has resurfaced, and investors are searching for a framework that can adapt to rotation. A...
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence
BAAR, Switzerland--(BUSINESS WIRE)--Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence.
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026
Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. BMY's 2026 guidance and Q4 2025 results exceeded consensus, with ma...
Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade
Chris Boerner, Bristol Myers Squibb CEO, joins CNBC's "Power Lunch" to discuss the company's quarterly earnings results, the drug pipeline and much more.
Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript
Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript
Dow Tumbles Over 400 Points; Bristol Myers Reports Strong Q4 Results
Bristol Myers Squibb & Co. (NYSE:BMY) reported better-than-expected results for the fourth quarter.
Bristol Myers Flags Data-Rich 2026 After Solid Quarter
Bristol Myers Squibb & Co. (NYSE: BMY) reported fourth-quarter 2025 revenues of $12.50 billion on Thursday, beating the consensus of $12.281 billion, a 1% increase year over year.
Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors.
Bristol Myers Squibb issues an especially upbeat outlook for 2026.
Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth
Bristol Myers Squibb reported higher fourth-quarter revenue as growth in sales of its immuno-oncology treatments helped to offset a decline in revenue for some of its older drugs.
Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off
Bristol Myers Squibb on Thursday forecast 2026 results above Wall Street estimates, saying that price cuts to its blood thinner Eliquis will help drive up revenue.
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025.
OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb
Oxford, UK – 4 February 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has expanded its strategic partnership with Bristol Myers Squibb (“BMS”...
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi.
Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FXIa--Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care.
Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)
Bristol Myers Squibb (BMY) has delivered a ~27% total return in three months, driven by topline growth and dividend strength. With the valuation rebound largely complete, BMY shifts from a high-convic...
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
Bristol-Myers Squibb (BMY) remains a Strong Buy as it accelerates Growth Portfolio revenues and executes strategic oncology expansion. BMY's collaboration with Janux Therapeutics positions it to enter...